RxDoctor Payments Data

Jessica van Mason, MD

Allergy & Immunology · Chattanooga, TNNPI 1225422280

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,750, more than ten times the $165 reported in 2019. That places this record below the midpoint for allergy & immunology clinicians in TN, where the typical reported total is $6,300.

$4,631in general payments, 2019–2025

Across 213 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$921
  • Sanofi$559
  • Takeda Pharmaceuticals U.S.A., Inc.$515
  • AstraZeneca$437
  • GSK$426
  • Grifols USA, LLC$303
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,619100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,631 in reported general payments places this provider in the 40th percentile of 79 allergy & immunology providers in Tennessee.

See all allergy & immunology providers in Tennessee

Medicare billing

Part B allowed, 2024
$102,650
Medicare patients
141
Services billed
5,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$21,371
Olopatadine Hcl61$5,899
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate30$5,839
SymbicortBudesonide/Formoterol Fumarate14$3,480
BreynaBudesonide/Formoterol Fumarate15$2,765
Epinephrine16$2,656
Azelastine Hcl53$1,978
Ipratropium Bromide36$1,681
Fluticasone Propionate101$1,113
Albuterol Sulfate HfaAlbuterol Sulfate32$888
Montelukast Sodium77$665
Hydroxyzine Hcl20$284
Famotidine20$173
Levocetirizine Dihydrochloride17$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$426$21,37122 claims
AstraZenecaSymbicort$437$3,48014 claims
Hikma Pharmaceuticals USAEpinephrine$20$2,65616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 79 allergy & immunology providers in Tennessee.

Other allergy & immunology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →